Business
Vicore to Present at Pareto Securities' 16th Annual Healthcare Conference
STOCKHOLM, SE / ACCESS Newswire / September 15, 2025 /Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation at Pareto Securities' 16th ...
About this update from Vicore Pharma Holding Ab
[{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / September 15, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation at Pareto Securities' 16th Annual Healthcare Conference 2025:","length":288,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Location: Stockholm, Sweden","length":27,"tagName":"p"}]},{"val":[{"type":"text","content":"Format: Presentation and 1×1 meetings","length":37,"tagName":"p"}]},{"val":[{"type":"text","content":"Presentation Date and Time: Tuesday, September 16 at 3:45 PM CEST","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Participants: Hans Jeppsson, CFO, and Bertil Lindmark, CMO","length":58,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":187,"olType":false},{"type":"text","content":"The company's management will also be available for meetings at the conference.","length":83,"tagName":"p"},{"type":"text","content":"More information about the event can be found on Pareto's webpage:https://paretosec.com/updates/events-and-conferences","length":123,"tagName":"p"},{"type":"text","content":"For further information, please contact:Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, [email protected] Jeppsson, CFO, tel: +46 70 553 14 65, [email protected]","length":234,"tagName":"p"},{"type":"text","content":"About Vicore PharmaVicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.","length":594,"tagName":"p"},{"type":"text","content":"The company is publicly listed on the Nasdaq Stockholm exchange (VICO). www.vicorepharma.com","length":92,"tagName":"p"},{"type":"text","content":"AttachmentsVicore to Present at Pareto Securities' 16th Annual Healthcare Conference",...